NervGen Pharma Company Insiders
| NGEN Stock | CAD 3.00 0.13 4.15% |
NervGen Pharma employs about 7 people. The company is managed by 7 executives with a total tenure of roughly 0 years, averaging almost 0.0 years of service per executive, having 1.0 employees per reported executive. Recap of NervGen Pharma's management performance can provide insight into the venture performance.
NervGen |
NervGen Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.5314) % which means that it has lost $0.5314 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.3027) %, meaning that it generated substantial loss on money invested by shareholders. NervGen Pharma's management efficiency ratios could be used to measure how well NervGen Pharma manages its routine affairs as well as how well it operates its assets and liabilities. At this time, NervGen Pharma's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 11.70 in 2024, whereas Return On Tangible Assets are likely to drop (1.85) in 2024. Intangibles To Total Assets is likely to climb to 0.07 in 2024, whereas Total Assets are likely to drop slightly above 11.3 M in 2024.Common Stock Shares Outstanding is likely to drop to about 41.5 M in 2024. Net Loss is likely to climb to about (17.7 M) in 2024
NervGen Pharma Workforce Comparison
NervGen Pharma Corp is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 2,969. NervGen Pharma adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
NervGen Pharma Corp Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. NervGen Pharma Corp Price Series Summation is a cross summation of NervGen Pharma price series and its benchmark/peer.
NervGen Pharma Notable Stakeholders
A NervGen Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as NervGen Pharma often face trade-offs trying to please all of them. NervGen Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting NervGen Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michael Kelly | President CEO | Profile | |
| William BASc | CoFounder Chairman | Profile | |
| Brian McAlister | CoFounder Advisor | Profile | |
| Harold DMD | CoFounder Director | Profile | |
| Elizabeth BSc | Senior Management | Profile | |
| Adam MD | Interim Director | Profile | |
| Charles DSc | Senior Operations | Profile |
About NervGen Pharma Management Performance
The success or failure of an entity such as NervGen Pharma Corp often depends on how effective the management is. NervGen Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of NervGen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the NervGen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.76) | (1.85) | |
| Return On Capital Employed | 9.34 | 9.81 | |
| Return On Assets | (1.69) | (1.78) | |
| Return On Equity | 11.14 | 11.70 |
Please note, the imprecision that can be found in NervGen Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of NervGen Pharma Corp. Check NervGen Pharma's Beneish M Score to see the likelihood of NervGen Pharma's management manipulating its earnings.
NervGen Pharma Workforce Analysis
Traditionally, organizations such as NervGen Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare NervGen Pharma within its industry.NervGen Pharma Manpower Efficiency
Return on NervGen Pharma Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 3.2M | |
| Net Loss Per Executive | 3.2M |
Additional Tools for NervGen Stock Analysis
When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.